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HIGHLIGHTS
 Dose selection for new combination therapy in tuberculosis has remained empirical. 
 Novel tools are needed for effective translation of preclinical models to humans. 
 A model-based approach is needed to support dose rationale and better trial 
designs. 
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Teaser: Trial and error have prevailed in the development of drugs for tuberculosis (TB). Understanding of the 
pharmacokinetics/pharmacodynamics (PKPD) relation is crucial for the selection of doses of antibacterial drugs in 
humans. Here, we propose an integrated approach to guide efficient development of anti-TB drug combinations.
Despite promising advances in the field and highly effective first-line treatment, an estimated 9.6 million people are still 
infected with tuberculosis (TB). Innovative methods are required to effectively transition the growing number of 
compounds into novel combination regimens. However, progression of compounds into patients occurs despite the 
lack of clear understanding of the pharmacokinetic-pharmacodynamic (PK/PD) relations. The PreDiCT-TB consortium 
was established in response to the existing gaps in TB drug development. The aim of the consortium is to develop new
preclinical tools in concert with an in silico model-based approach, grounded in PKPD principles. Here, we highlight
the potential impact of such an integrated framework on various stages in TB drug development and on the dose 
rationale for drug combinations.
Introduction
The development of new combination therapies for TB is lengthy and costly [1]. Despite promising advances in the 
field, innovative methods are still needed to effectively transition the growing number of compounds into novel 
combination regimens. Among other things, it is essential to shorten current treatment regimens and tackle 
multidrug-resistant TB.
Shift in the TB drug development paradigm: reality or fiction?
The disappointing results from all recent Phase III trials of TB drugs [2–5] clearly demonstrate that a shift in 
paradigm is needed in TB drug development. Insufficient efficacy is the main cause for failures in clinical drug 
development [6,7]. Achieving efficacious drug exposure at the site of action is imperative for producing the desired 
response (i.e., reducing or preventing relapses). Nevertheless, the decision-making process in Phase II or III trials 
has remained empirical and recent development programs have progressed with limited PKPD knowledge to 
support the dose selection and study design. Clearly, dose selection must be based on evaluation of the PK
properties and concentration effect (PKPD) relation of each drug, rather than by trial and error. Such concerns are 
also applicable to the most common approach to dose selection (i.e., the use of currently approved doses for the 
background standard of care treatment).
The challenges above are compounded by another major bottleneck in the development pathway in that current 
regulatory guidelines support the need for a long and often poorly informative range of studies. The rationale for
testing different doses, regimens, and sequence of add-on drugs of each potential combination is clearly inefficient 
[8]. At least 6 years (an estimated 1 year for Phase I, 2 years for Phase II, and 3 years for Phase III) are required to 
develop one new antibiotic [1], whereas more than two decades (46 years) would be needed for the development 
and approval of a completely novel regimen comprising four new antibiotics through successive trials [1]. Here, we
focus on how an integrated PKPD–disease modelling and simulation framework, also known as model-informed 
drug discovery and development (MID3), could accelerate the development of novel combination therapies and 
highlight the potential impact of such framework to inform more robust decision making in TB drug development.
Historically, the approval of current first short-course therapy for TB was preceded by sequential testing of 
promising candidates in preclinical experiments, which were then followed by clinical studies under the 
sponsorship of the British Medical Research Council (BMRC) during the 1970s and 1980s [9]. These drugs were 
approved based on the traditional paradigm in drug development in which the progression of candidates depended
on a sequential decision-making process; that is, each phase is considered as a discrete step that is successfully 
completed as soon as predefined targets or criteria are met. However, this approach does not provide the flexibility 
that is required to rapidly and effectively assess multiple new combination regimens in a single development 
program. Yet, new anti-TB drugs or combinations are still assessed according to the same linear pathway before 
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moving to large trials in which the new drug is added to, or used as substitution for, one of the drugs in the 
standard regimen [10,11]. Most alarming is the lack of a strong scientific basis for the selection of doses and dosing 
regimens for TB, which is one of the major poverty-related diseases.
PreDiCT-TB: a quantitative framework for TB drug development
A robust quantitative framework is required to integrate data and facilitate effective translation of preclinical 
findings to humans. To that purpose, PreDiCT-TB, an Innovative Medicines Initiative (IMI)-funded project 
comprising pharmaceutical research and development (R&D) and academic partners, has proposed the 
development of model-informed approaches to address some of the existing gaps in TB drug development. In 
particular, attention is given to opportunities for improved evidence generation as well as evidence synthesis for
the evaluation of new, more effective combinations of treatments. PKPD–disease modelling and simulation have 
been established as powerful tools for the characterisation of efficacy and safety in other therapeutic areas [12,13]. 
Their impacts on therapeutics and drug development have been reviewed extensively elsewhere [14]. A formal 
modelling framework that integrates data arising from novel or existing preclinical models and historical clinical 
studies is envisaged to inform decision-making at different stages of development; that is, optimisation of 
experimental protocols and sampling schemes and the design of the subsequent studies or termination of the 
project [15]. Most importantly, it enables comprehensive evaluation of the dose rationale [16].
Within PreDiCT-TB, a set of carefully selected anti-TB drugs (licensed and unlicensed) is being evaluated using
standard and novel preclinical models. In parallel, a comprehensive database comprising individual patient data
from historical clinical trials will be established for use as a reference for evaluating the performance of multiple 
anti-TB drug regimens, as assessed by preclinical models. These results will be used to refine experimental protocol 
conditions and identify experimental designs that are most informative; that is, provide evidence of the underlying 
concentration–effect relations or support the translation of drug effects in humans [17]. Both preclinical and 
clinical data will then contribute to the development and validation of a PKPD–disease modelling and simulation 
framework, which is intended to support the progression of candidate molecules into clinical development. Among 
the key deliverables of the consortium are the evaluation of (adaptive) study designs and translational research 
platforms for novel combination therapies for TB (Figures 1 and 2). An overview of current recommendations for 
the implementation of a model-informed approach as envisaged by PreDiCT-TB is presented in Table 1.
Evidence generation and synthesis at candidate selection
The availability of preclinical models that reflect key human pathological features of TB infection would be a 
valuable tool for translating PKPD concepts, offering a strong rationale for clinical trial designs [18,19]. If designed 
properly, such experiments could also facilitate the characterisation of PKPD relations of drugs in combination 
therapies, providing insight into exposure levels that correspond with optimal effect. Based on this approach, 
preclinical findings should form the basis for dose selection in humans and support the design of subsequent 
clinical studies [18].
TB has seen many exciting advances in preclinical research [20,21]. In vitro and animal models are becoming 
more sophisticated and have enabled us to generate more insight regarding the immunopathology of the disease 
and the interaction between various Mycobacterium tuberculosis (Mtb) subpopulations [22]. However, given the 
major differences in TB susceptibility and histopathology that currently exist between animal models, it is unlikely 
that a single experimental system will become available that could fully mimic the infection process in humans. In 
addition, large variability is observed in in vivo efficacy studies depending on the choice of Mtb strain [23]. In most 
cases, these experiments rely on limited information about drug combinations, range of doses, or dosing intervals. 
Consequently, the translation of pr clinical data to inform suitable combinations and appropriate dosing regimens 
in clinical trials is anything but accurate.
PKPD–disease models can be developed to systematically characterise the differences in disease condition and 
evaluate the impact of combination therapies on the PKPD relation of backbone treatment in various animal 
models. It can be anticipated that the use of such models may allow: (i) the refinement of experimental protocols, 
consequently reducing the sample size needed in preclinical studies without compromising the precision of 
information derived from the experiment; (ii) inform prioritisation of the best drug combinations to be tested in 
clinical development; and (iii) systematically evaluate the performance of various preclinical models against 
available human data. Even if shortcomings were found in the translation of findings, the use of a model-informed 
approach does represent a considerable improvement in terms of the 3 Rs (reduction, replacement, and refinement).
Evidence generation and evidence synthesis during clinical drug development
Once the best predictive preclinical models are identified, clinical trial simulations (CTS) can be harnessed to 
evaluate an unlimited number of experimental scenarios (i.e., drug combinations, dose selection, sampling times, 
and sample sizes) in a systematic manner to identify the best clinical study design. For example, CTS has been
successfully used to support selection of the dose range of antibiotics in Phase II/III studies by integrating data on 
the distribution of minimum inhibitory concentration (MIC) for clinical isolates with the PD target(s) developed 
from animal models of infection and PK characteristics of the compound [24]. By contrast, Phase II studies have 
often ignored PK variability and other sources of variation in treatment response in the target patient population, 
which need to be accounted for when exploring the dose–exposure–response relation. The impact of CTS during 
clinical development by means of providing stronger support for regulatory approval and labelling has been 
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established in other therapeutic areas [12,25] and acknowledged by regulatory agencies [26]. Given that only a
limited number of combinations can be tested in humans, it is crucial to harness methods that facilitate more 
robust study design and dose-range selection before the start of the trial. If necessary, data from Phase IIa can be 
used prospectively to refine the PKPD–disease model and increase its performance to assess the most appropriate
Phase IIb and III study protocol (i.e., patient population, dose, sample size, sampling time, treatment duration, and 
drug combinations). Moreover, additional factors, such as different compliance patterns and other comorbidities,
can be included into the simulation scenarios when evaluating the dose rationale for antibiotics that are used in a 
chronic manner. Ultimately, this approach allows one to explore the impacts of critical factors on treatment 
response and address crucial questions regarding the experimental protocol before the trial is conducted.
Results from Phase II and III trials have been traditionally reported without linking treatment outcome with 
individual drug exposure. However, the availability of such data could explain the variability in response and,
hence, provide insight into whether any unsuccessful trial outcome might be attributed to underexposure to the 
drugs, rather than the novel regimen truly being inferior to the standard of care. Considering the cost and burden 
of Phase II and III trials, the integration of PK to efficacy trials should become a mandatory component of clinical 
protocols. MIDs can be implemented that require sparse PK sampling, yielding accurate and precise estimation 
drug exposure in individual patients [27]. A PKPD analysis can subsequently be performed to evaluate the relation
between drug exposure and clinical response.
Another important aspect regarding the evaluation of clinical response is the lack of consensus regarding the 
relevance of different endpoints in clinical trials (e.g., colony-forming unit count versus time to positivity). The 
concurrent use of different measures and regimen has made the comparison of historical and modern clinical trials 
challenging [28]. Rather than neglecting historical data, in silico models can be used to characterise the relation
between different measures of bacterial load [29]. The availability of such models will enable researchers to utilise 
as many existing data as possible to inform decision-making in TB drug development in a more robust manner.
Challenges for the implementation of a model-informed approach at candidate selection
The success of the proposed model-informed approach depends on the availability of suitable experimental data for 
the development of robust in silico models. This requirement is not trivial, in that most experimental protocols 
might only provide insight into the underlying PKPD relations. These limitations are often determined by costs and 
time constraints. However, even when full PKPD relations are characterised, discrepancies between animal models 
still pose a major challenge in extrapolating model predictions into clinical doses. Difference in bacterial strain
(e.g., H37Rv versus Erdman), pathology (e.g., absence versus presence of necrotic lesions) or treatment condition
(e.g., onset and duration of treatment) can yield significantly different PKPD parameters and, hence, varying
predictions of the clinical dose.
Efforts are being made within PreDiCT-TB to overcome some of these challenges. The consortium has identified 
a range of in vitro and in vivo models and performed a variety of experiments to compare the differences in PKPD
relations of various anti-TB regimens. Even though the current clinical regimens with isoniazid, rifampicin, 
ethambutol, and pyrazinamide are not truly optimised, evidence of differences in the PK and PD of standard drugs
across experimental models will provide insight into the sensitivity and specificity of these models to detect the 
bactericidal, bacteriostatic, and sterilising activity of compounds currently used in humans.
Challenges for the implementation of a model-informed approach in clinical drug development
Most of the known issues for the clinical development of anti-TB agents cannot be overcome by PreDiCT-TB alone.
First, variability in PK continues to be overlooked. Collection of individual drug exposure is not included as a 
standard procedure in clinical protocols and blood sampling might not even be feasible in high-burden countries,
where most Phase III TB trials are performed. In addition, even if individual PKPD data were collected, such as 
sputum conversion, information from a single measurement at the time of relapse would be insufficient to allow the 
development of predictive models for the detection of relapse. In addition to further understanding of the
underlying biological mechanisms of relapse, it is crucial to obtain repeated microbiological data during treatment 
and follow-up. From a drug development perspective, what appears to become clear from early bactericidal activity
(EBA) studies is that information on early bactericidal activity might not be a suitable descriptor of the processes 
associated with relapse. Another important limitation of EBA studies is that the PKPD relation based on drug 
levels in plasma might not describe tissue exposure. Similarly, a viable colony-forming unit count in sputum might
not represent the whole Mtb population in the human lung.
Despite such limitations, the opportunity to replace the empirical basis upon which doses are selected will 
represent an important advancement for therapeutics with novel anti-TB drugs. Last, but not least, the consortium 
has managed to collate data from historical studies, creating a pool of individual patient-level data that will 
facilitate the evaluation of the proposed framework for drug combinations.
Consequences for regulatory approval
Clearly, translation of the advancements obtained so far with regard to our increased understanding of the 
pathophysiology of infection by Mtb and improved knowledge of drug disposition and PKPD properties in tissues 
and target organs demands more than just the effective implementation of the MID3 concepts highlighted above. 
Regulatory acceptance and guidance needs to evolve to ensure that lessons from this growing field are embedded 
into the drug approval process. A proactive attitude by regulatory authorities has been observed over the past few 
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years, in that a concept paper and new guidance have been issued that focus on the development of entirely new 
regimens to treat TB, rather than focusing on single medicines.
Recently, the European Medicines Agency (EMA) opened a consultation for updating the guideline on the 
evaluation of medicinal products indicated for treatment of bacterial infections [30]. Whereas the use of in vitro PD
models, such a the hollow fibre system, has been endorsed for dose selection early on during the development 
program, further insight from translational pharmacology and clinical trial simulations might have an important 
role in minimising the extent of dose- and/or regimen-finding clinical trials. Therefore, to be effective, the new 
guidance should establish the mechanisms by which novel approaches for data generation and integration will be 
considered in future regulatory submissions. In this respect, a dialogue between public–private initiative
partnerships and regulatory agencies is timely and crucial. Most importantly, regulators and experts need to weigh 
the importance of alternative endpoints and study designs for the approval of new medicines or combinations of 
medicines along with the role of biomarkers to predict the efficacy and effectiveness of alternative regimens during 
clinical development.
Concluding remarks
Improved efficiency in the development of drug combinations is urgently needed for the advancement of new 
treatments for TB. PreDiCT-TB has been created to overcome some of the crucial gaps during early drug 
development and revolutionise the way evidence is generated and integrated to support the progression of 
candidate molecules into humans. The implementation of a model-informed approach to the design, analysis, and 
interpretation of experimental data during preclinical phases of development will provide a more robust basis for 
the selection of suitable combinations and translate the appropriate dosing regimens for first-time use in patients. 
In conjunction with clinical trial simulations, PreDiCT-TB expects to demonstrate the relevance of more 
informative clinical trial designs and offer regulatory agencies a stronger scientific basis for the approval of 
treatments in a therapeutic area that has remained neglected for the past four decades.
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Figure 1. [LM3]Diagram describing the individual components of the integrated pharmacokinetics/pharmacodynamics (PKPD)–disease modelling and simulation 
framework. The disease model encompasses the natural growth and elimination rate of Mycobacterium tuberculosis (Mtb) in the absence of antibiotics. The drug model 
characterises the PK and PKPD properties as well as any covariate effects on the disposition or PD of the drug. In addition to the disease and drug components, a trial 
model is used to assess treatment performance in the context of a clinical trial protocol. Among other factors, a trial model allows the assessment of the impact of
dropouts, inclusion/exclusion criteria, or compliance on trial outcome. Adapted from [31].
Figure 2. [LM4]A schematic overview of how a pharmacokinetics/pharmacodynamics (PKPD)–disease modelling and simulation framework can be applied to 
translate preclinical findings and identify the appropriate doses and dosing regimens for tuberculosis drugs for first-time use in patients from preclinical experiments. 
Assuming the availability of data supporting the characterisation of dose/exposure–response relations in vitro and in vivo (A), in silico models can be developed that 
characterise the PK and PKPD properties of the drug combinations of interest (B). After correcting for the interspecies differences in physiology and/or physiochemical 
properties, parameter estimates can subsequently be used to either scale preclinical findings to humans or to facilitate the translation of drug effects taking into account 
differences between experimental and clinical conditions. Clinical trial simulations can be performed to inform the range of doses of each antibiotic that is expected to 
yield exposure levels (shaded green area) that are associated with the desired effect (dashed line) in preclinical experiments (C).
Table 1. Overview of recommendations of how a model-based approach can be used to address the current gaps in various 
stages of TB drug development
Development stage Current gaps Recommendations for the implementation of MID3
Limited value of preclinical experimental protocol 
designs, which often do not provide insight into the PK 
and PKPD relations
Adapt experimental protocols to ensure characterisation of the PKPD 
relations while allowing for experiments with fewer animals and optimised
sampling and dosing schedules
Lack of quantitative methods to systematically integrate 
PK or PKPD findings arising from different experimental 
models
Develop integrated models for the systematic evaluation of the implications 
of differences across species and/or experimental conditions
Preclinical 
Uncertainty about the predictive value of preclinical 
experiments and lack of tools to account for 
uncertainties into the decision-making process 
Incorporation of historical data and mechanism-based and physiologically
based PK (PBPK) models into the dose rationale in patients
Progression of a compound into clinical development 
based on a weak dose rationale and lack of 
understanding of the relation between drug exposure 
and clinical outcome (i.e., relapse or time to positivity)
Focus on the underlying PKPD relation and monitoring of PK and PD over 
time using a sparse sampling strategy; in addition, availability of 
longitudinal data at individual patient level might provide an opportunity to 
assess the impact different sources of variability during Phase II or III trials 
Clinical
Lack of systematic (quantitative) integration of historical 
data, partly because of the use of different clinical 
measures (endpoints) in old and recent clinical trials
Explore the utility of mechanism-based parameterisation that supports the 
characterisation of bacterial growth and killing as the primary processes 
underlying time to positivity
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